Envestnet Asset Management’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.01M Buy
42,194
+10,662
+34% +$296K ﹤0.01% 3470
2025
Q4
$874K Sell
31,532
-7,735
-20% -$197K ﹤0.01% 3350
2025
Q3
$953K Buy
39,267
+4,419
+13% +$87.9K ﹤0.01% 3345
2025
Q2
$593K Buy
34,848
+5,166
+17% +$90K ﹤0.01% 3581
2025
Q1
$580K Sell
29,682
-785
-3% -$20.6K ﹤0.01% 3532
2024
Q4
$756K Buy
30,467
+2,296
+8% +$58.6K ﹤0.01% 3341
2024
Q3
$690K Buy
28,171
+7,633
+37% +$197K ﹤0.01% 3344
2024
Q2
$481K Sell
20,538
-1,602
-7% -$39.3K ﹤0.01% 3479
2024
Q1
$732K Buy
22,140
+97
+0.4% +$3.02K ﹤0.01% 3220
2023
Q4
$600K Buy
22,043
+11,900
+117% +$296K ﹤0.01% 3237
2023
Q3
$244K Sell
10,143
-5,098
-33% -$137K ﹤0.01% 3646
2023
Q2
$487K Buy
15,241
+2,377
+18% +$77.1K ﹤0.01% 3225
2023
Q1
$394K Buy
12,864
+5,244
+69% +$207K ﹤0.01% 3302
2022
Q4
$298K Buy
7,620
+2,040
+37% +$91.4K ﹤0.01% 3431
2022
Q3
$266K Buy
+5,580
New +$318K ﹤0.01% 3421
2022
Q2
Sell
-3,552
Closed -$204K 3923
2022
Q1
$204K Buy
+3,552
New +$233K ﹤0.01% 3674
2021
Q4
Sell
-4,950
Closed -$431K 3872
2021
Q3
$431K Buy
+4,950
New +$497K ﹤0.01% 3057

Other funds holding BEAM

Envestnet Asset Management's BEAM Position: Q1 2026 in Review

Envestnet Asset Management increased its Beam Therapeutics (BEAM) stake by 34% in Q1 2026, buying an estimated $296K and bringing the position to 42,194 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3470.

Envestnet Asset Management first reported a position in BEAM in Q3 2021 and has held it in 17 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Envestnet Asset Management held 42,194 shares of Beam Therapeutics worth $1.01M as of Q1 2026.
  • Envestnet Asset Management bought 10,662 Beam Therapeutics shares in Q1 2026, an estimated $296K.
  • Beam Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q1 2026, its #3470 holding.
  • Envestnet Asset Management first reported a position in Beam Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.